135 related articles for article (PubMed ID: 36585038)
1. Bortezomib inhibits hepatocellular carcinoma via the Hippo-Yes-associated protein signalling pathway.
Liao Y; Hu K; Liu W; Wang W; Qiu H; Pan S; Lv Q; Xu G
Basic Clin Pharmacol Toxicol; 2023 Apr; 132(4):297-311. PubMed ID: 36585038
[TBL] [Abstract][Full Text] [Related]
2. Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.
Zhao S; Xu K; Jiang R; Li DY; Guo XX; Zhou P; Tang JF; Li LS; Zeng D; Hu L; Ran JH; Li J; Chen DL
Life Sci; 2020 Jun; 251():117424. PubMed ID: 32057900
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells.
Wang C; Zhu ZM; Liu CL; He XJ; Zhang HY; Dong JH
Mol Med Rep; 2015 Jun; 11(6):4101-8. PubMed ID: 25625370
[TBL] [Abstract][Full Text] [Related]
4. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
[TBL] [Abstract][Full Text] [Related]
5. Retinal dehydrogenase 5 (RHD5) attenuates metastasis via regulating HIPPO/YAP signaling pathway in Hepatocellular Carcinoma.
Hu H; Xu L; Luo SJ; Xiang T; Chen Y; Cao ZR; Zhang YJ; Mo Z; Wang Y; Meng DF; Yu L; Lin LZ; Zhang SJ
Int J Med Sci; 2020; 17(13):1897-1908. PubMed ID: 32788868
[TBL] [Abstract][Full Text] [Related]
6. Tubuloside B, a major constituent of Cistanche deserticola, inhibits migration of hepatocellular carcinoma by inhibiting Hippo-YAP pathway.
Yao J; Wan H; Zhang J; Shen W; Wei X; Shi C; Ou B; Liu D; Ge L; Fei J; Zeng X
Phytomedicine; 2024 Jul; 129():155552. PubMed ID: 38552378
[TBL] [Abstract][Full Text] [Related]
7. Artemisinin suppresses hepatocellular carcinoma cell growth, migration and invasion by targeting cellular bioenergetics and Hippo-YAP signaling.
Li Y; Lu J; Chen Q; Han S; Shao H; Chen P; Jin Q; Yang M; Shangguan F; Fei M; Wang L; Liu Y; Liu N; Lu B
Arch Toxicol; 2019 Nov; 93(11):3367-3383. PubMed ID: 31563988
[TBL] [Abstract][Full Text] [Related]
8. CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ.
Hao X; Zhang Y; Shi X; Liu H; Zheng Z; Han G; Rong D; Zhang C; Tang W; Wang X
J Exp Clin Cancer Res; 2022 Sep; 41(1):281. PubMed ID: 36131287
[TBL] [Abstract][Full Text] [Related]
9. The hypoxia conditioned mesenchymal stem cells promote hepatocellular carcinoma progression through YAP mediated lipogenesis reprogramming.
Liu Y; Ren H; Zhou Y; Shang L; Zhang Y; Yang F; Shi X
J Exp Clin Cancer Res; 2019 May; 38(1):228. PubMed ID: 31142342
[TBL] [Abstract][Full Text] [Related]
10. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
[TBL] [Abstract][Full Text] [Related]
11. Yes-associated protein (YAP) binds to HIF-1α and sustains HIF-1α protein stability to promote hepatocellular carcinoma cell glycolysis under hypoxic stress.
Zhang X; Li Y; Ma Y; Yang L; Wang T; Meng X; Zong Z; Sun X; Hua X; Li H
J Exp Clin Cancer Res; 2018 Sep; 37(1):216. PubMed ID: 30180863
[TBL] [Abstract][Full Text] [Related]
12. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
Wong KF; Liu AM; Hong W; Xu Z; Luk JM
Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
[TBL] [Abstract][Full Text] [Related]
13. Deregulation of Hippo kinase signalling in human hepatic malignancies.
Li H; Wolfe A; Septer S; Edwards G; Zhong X; Abdulkarim AB; Ranganathan S; Apte U
Liver Int; 2012 Jan; 32(1):38-47. PubMed ID: 22098159
[TBL] [Abstract][Full Text] [Related]
14. Decursin inhibits the growth of HepG2 hepatocellular carcinoma cells via Hippo/YAP signaling pathway.
Li J; Wang H; Wang L; Tan R; Zhu M; Zhong X; Zhang Y; Chen B; Wang L
Phytother Res; 2018 Dec; 32(12):2456-2465. PubMed ID: 30251417
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Rac GTPase Activating Protein 1 Contributes to Proliferation of Cancer Cells by Reducing Hippo Signaling to Promote Cytokinesis.
Yang XM; Cao XY; He P; Li J; Feng MX; Zhang YL; Zhang XL; Wang YH; Yang Q; Zhu L; Nie HZ; Jiang SH; Tian GA; Zhang XX; Liu Q; Ji J; Zhu X; Xia Q; Zhang ZG
Gastroenterology; 2018 Oct; 155(4):1233-1249.e22. PubMed ID: 30009820
[TBL] [Abstract][Full Text] [Related]
16. Fingolimod exerts
Du J; Qian M; Yuan T; Zhang B; Chen X; An N; He Q; Yang B; Ye S; Zhu H
Acta Pharm; 2022 Sep; 72(3):427-436. PubMed ID: 36651547
[TBL] [Abstract][Full Text] [Related]
17. LMO3 promotes hepatocellular carcinoma invasion, metastasis and anoikis inhibition by directly interacting with LATS1 and suppressing Hippo signaling.
Cheng Y; Hou T; Ping J; Chen T; Yin B
J Exp Clin Cancer Res; 2018 Sep; 37(1):228. PubMed ID: 30219064
[TBL] [Abstract][Full Text] [Related]
18. SEPT6 drives hepatocellular carcinoma cell proliferation, migration and invasion via the Hippo/YAP signaling pathway.
Fan Y; Du Z; Ding Q; Zhang J; Op Den Winkel M; Gerbes AL; Liu M; Steib CJ
Int J Oncol; 2021 Jun; 58(6):. PubMed ID: 33846777
[TBL] [Abstract][Full Text] [Related]
19. Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma.
Kim W; Khan SK; Liu Y; Xu R; Park O; He Y; Cha B; Gao B; Yang Y
Gut; 2018 Sep; 67(9):1692-1703. PubMed ID: 28866620
[TBL] [Abstract][Full Text] [Related]
20. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
